Research ArticleBasic Science Investigations
Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates
Dieter Ory, Sofie Celen, Rik Gijsbers, Chris Van Den Haute, Andrey Postnov, Michel Koole, Caroline Vandeputte, José-Ignacio Andrés, Jesus Alcazar, Meri De Angelis, Xavier Langlois, Anindya Bhattacharya, Mark Schmidt, Michael A. Letavic, Wim Vanduffel, Koen Van Laere, Alfons Verbruggen, Zeger Debyser and Guy Bormans
Journal of Nuclear Medicine September 2016, 57 (9) 1436-1441; DOI: https://doi.org/10.2967/jnumed.115.169995
Dieter Ory
1Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
2Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Sofie Celen
1Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Rik Gijsbers
2Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
3Leuven Viral Vector Core, KU Leuven, Leuven, Belgium
Chris Van Den Haute
3Leuven Viral Vector Core, KU Leuven, Leuven, Belgium
4Laboratory for Neurobiology and Gene Therapy, Department of Neurosciences, KU Leuven, Leuven, Belgium
Andrey Postnov
5Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospital and KU Leuven, Leuven, Belgium
Michel Koole
5Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospital and KU Leuven, Leuven, Belgium
Caroline Vandeputte
5Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospital and KU Leuven, Leuven, Belgium
José-Ignacio Andrés
6Janssen Research and Development, Discovery Sciences, a Division of Janssen-Cilag, Toledo, Spain
Jesus Alcazar
6Janssen Research and Development, Discovery Sciences, a Division of Janssen-Cilag, Toledo, Spain
Meri De Angelis
6Janssen Research and Development, Discovery Sciences, a Division of Janssen-Cilag, Toledo, Spain
Xavier Langlois
6Janssen Research and Development, Discovery Sciences, a Division of Janssen-Cilag, Toledo, Spain
Anindya Bhattacharya
6Janssen Research and Development, Discovery Sciences, a Division of Janssen-Cilag, Toledo, Spain
7Janssen Research and Development, LLC, San Diego, California
Mark Schmidt
8Janssen Research and Development, Neuroscience Discovery, a Division of Janssen Pharmaceutica Nevada, Beerse, Belgium; and
Michael A. Letavic
7Janssen Research and Development, LLC, San Diego, California
Wim Vanduffel
9Laboratory for Neuro- and Psychophysiology, Department of Neurosciences, KU Leuven, Leuven, Belgium
Koen Van Laere
5Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospital and KU Leuven, Leuven, Belgium
Alfons Verbruggen
1Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Zeger Debyser
2Laboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Guy Bormans
1Laboratory for Radiopharmacy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 9
September 1, 2016
Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates
Dieter Ory, Sofie Celen, Rik Gijsbers, Chris Van Den Haute, Andrey Postnov, Michel Koole, Caroline Vandeputte, José-Ignacio Andrés, Jesus Alcazar, Meri De Angelis, Xavier Langlois, Anindya Bhattacharya, Mark Schmidt, Michael A. Letavic, Wim Vanduffel, Koen Van Laere, Alfons Verbruggen, Zeger Debyser, Guy Bormans
Journal of Nuclear Medicine Sep 2016, 57 (9) 1436-1441; DOI: 10.2967/jnumed.115.169995
Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates
Dieter Ory, Sofie Celen, Rik Gijsbers, Chris Van Den Haute, Andrey Postnov, Michel Koole, Caroline Vandeputte, José-Ignacio Andrés, Jesus Alcazar, Meri De Angelis, Xavier Langlois, Anindya Bhattacharya, Mark Schmidt, Michael A. Letavic, Wim Vanduffel, Koen Van Laere, Alfons Verbruggen, Zeger Debyser, Guy Bormans
Journal of Nuclear Medicine Sep 2016, 57 (9) 1436-1441; DOI: 10.2967/jnumed.115.169995
Jump to section
Related Articles
Cited By...
- TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study
- Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18F-JNJ-64413739, a PET Radioligand for P2X7 Receptors
- P2X7 PET Radioligand 18F-PTTP for Differentiation of Lung Tumor from Inflammation
- 18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446